Marker May Predict Response To Ipilimumab In Advanced Melanoma
Sunday, March 2, 2014 - 23:00
in Health & Medicine
PHILADELPHIA — Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research. The study suggests combining immunotherapy with VEGF inhibitors, also known as angiogenesis inhibitors, may be a potential option for these patients. read more